

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajsl1623

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS	4	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS	5	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS	6	JUN 29	EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS	7	JUL 09	PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS	8	JUL 14	USGENE enhances coverage of patent sequence location (PSL) data
NEWS	9	JUL 27	CA/CAPplus enhanced with new citing references
NEWS	10	JUL 16	GBFULL adds patent backfile data to 1855
NEWS	11	JUL 21	USGENE adds bibliographic and sequence information
NEWS	12	JUL 28	EPFULL adds first-page images and applicant-cited references
NEWS	13	JUL 28	INPADOCDB and INPAFAMDB add Russian legal status data
NEWS	14	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	15	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	16	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	17	AUG 24	CA/CAPplus enhanced with legal status information for U.S. patents
NEWS	18	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:38:46 ON 10 SEP 2009

=> b reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 13:38:55 ON 10 SEP 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 SEP 2009 HIGHEST RN 1181456-82-5

DICTIONARY FILE UPDATES: 8 SEP 2009 HIGHEST RN 1181456-82-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e cladribine/cn

E1	1	CLADRASTIN/CN
E2	1	CLADRASTIN 7-O-B-D-GLUCOSIDE/CN
E3	1 -->	CLADRIBINE/CN
E4	1	CLADRIBINE 5'-DIPHOSPHATE/CN
E5	1	CLADRIBINE 5'-MONOPHOSPHATE/CN
E6	1	CLADRIBINE 5'-TRIPHOSPHATE/CN
E7	1	CLADRIN/CN
E8	1	CLAENONE/CN
E9	1	CLAF EX/CN
E10	1	CLAF HS GRADE/CN
E11	1	CLAF HS (T) /CN
E12	1	CLAF MS (T) /CN

=> s e3

L1 1 CLADRIBINE/CN

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN

RN 4291-63-8 REGISTRY

ED Entered STN: 16 Nov 1984

CN Adenosine, 2-chloro-2'-deoxy- (CA INDEX NAME)

OTHER NAMES:

IN 7324 GENE CGT)/CN
 E9 1 CYCLODEXTRIN GLUCANOTRANSFERASE (BACILLUS G1-2004 PRECURSOR)
 /CN
 E10 1 CYCLODEXTRIN GLUCANOTRANSFERASE (BACILLUS STRAIN G1 PRECURSO
 R)/CN
 E11 1 CYCLODEXTRIN GLUCANOTRANSFERASE (PYROCOCCUS KODAKARAENSIS ST
 RAIN KOD1 GENE CGT PRECURSOR)/CN
 E12 1 CYCLODEXTRIN GLUCANOTRANSFERASE (STREPTOCOCCUS PYOGENES STRA
 IN MGAS10270 GENE AMYA)/CN

=> s e3

L2 1 CYCLODEXTRIN/CN

=> d 12

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN

RN 12619-70-4 REGISTRY

ED Entered STN: 16 Nov 1984

CN Cyclodextrin (CA INDEX NAME)

OTHER NAMES:

CN β -100

CN Celdex

CN Celdex CH 20

CN Celdex CH 30

CN Celdex SH 20

CN Celdex SH 40

CN Celdex SL 20

CN Celdex TB 50

CN Cycloamylose

CN Cyclodextrins

CN Rhodocap L 20

CN Ringdex P

CN Ringdex PK

CN Schardinger dextrin

DR 856575-11-6, 131076-21-6, 100091-36-9

MF Unspecified

CI COM, MAN

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS,
 CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU,
 EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, NAPRALERT, PIRA, PROMT, TOXCENTER,
 USPAT2, USPATFULL, USPATOLD

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7381 REFERENCES IN FILE CA (1907 TO DATE)

1869 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

7411 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> b caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

15.28

15.50

FILE 'CAPLUS' ENTERED AT 13:39:31 ON 10 SEP 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Sep 2009 VOL 151 ISS 11
FILE LAST UPDATED: 9 Sep 2009 (20090909/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAPLUS family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

```
=> s 11 and 12
      1493 L1
      7414 L2
L3      12 L1 AND L2

=> s 13 and py<=2004
      25141550 PY<=2004
L4      6 L3 AND PY<=2004

=> d 13 ibib abs 1-12
```

L3 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:1016541 CAPLUS
TITLE: Implantable biodegradable medical good impregnated
with magnetic particles and optionally drugs for
treatment following tumor surgery
INVENTOR(S): Jordan, Andreas
PATENT ASSIGNEE(S): Magforce Nanotechnologies AG, Germany
SOURCE: PCT Int. Appl., 45pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2009100716	A2	20090820	WO 2009-DE196	20090211
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM DE 102008008522 A1 20090813 DE 2008-102008008522 20080211 PRIORITY APPLN. INFO.: DE 2008-102008008522A 20080211 US 2008-71084P P 20080411				

AB The present invention relates to implantable and preferably biol. metabolizable medical products comprising nanoparticles, and the use thereof for thermotherapeutic treatment following surgical removal of tumors and cancers. ABSThe medical good is implanted after tumor surgery; magnetic field causes the beads to heat the wound area; in combination with a drug the antitumor and antimicrobial activity can be effected. Thus iron oxide magnetic particles were prepared from iron dichloride and iron trichloride solution by precipitation in sodium hydroxide; the suspension was diluted to 5 weight% iron oxide. A wound pad composed of calcium alginate and sodium CM-cellulose was impregnated with the nanoparticle-containing suspension.

L3 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:971041 CAPLUS
TITLE: Implantable biodegradable medical good impregnated with magnetic particles and optionally drugs for treatment following tumor surgery
INVENTOR(S): Jordan, Andreas
PATENT ASSIGNEE(S): Magforce Nanotechnologies AG, Germany
SOURCE: Ger. Offen., 19pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 102008008522	A1	20090813	DE 2008-102008008522	20080211
WO 2009100716	A2	20090820	WO 2009-DE196	20090211
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,				

TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

DE 2008-102008008522A 20080211

US 2008-71084P P 20080411

AB The invention concerns biodegradable medical goods that contain magnetic micro- or nanoparticles and optionally drugs. The medical good is implanted after tumor surgery; magnetic field causes the beads to heat the wound area; in combination with a drug the antitumor and antimicrobial activity can be effected. Thus iron oxide magnetic particles were prepared from iron dichloride and iron trichloride solution by precipitation in sodium hydroxide; the suspension was diluted to 5 weight% iron oxide. A wound pad composed of calcium alginate and sodium CM-cellulose was impregnated with the nanoparticle-containing suspension.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:674934 CAPLUS

DOCUMENT NUMBER: 149:17767

TITLE: Compositions of Chk1 kinase inhibitor for cancer treatment

INVENTOR(S): Colvin, Anita A.; Koppenol, Sandy; Wisdom, Wendy A.

PATENT ASSIGNEE(S): Icos Corporation, USA

SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008067027	A2	20080605	WO 2007-US80150	20071002
WO 2008067027	A3	20090416		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007325576	A1	20080605	AU 2007-325576	20071002
CA 2673483	A1	20080605	CA 2007-2673483	20071002
EP 2063879	A2	20090603	EP 2007-871106	20071002
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
IN 2009MN00498	A	20090522	IN 2009-MN498	20090309
KR 2009065537	A	20090622	KR 2009-707975	20090417
PRIORITY APPLN. INFO.:			US 2006-853056P P 20061020	
			WO 2007-US80150 W 20071002	

OTHER SOURCE(S): MARPAT 149:17767

AB Compns. containing at least one Chk1 kinase inhibitor and at lease one cyclodextrin are disclosed. Also disclosed are methods of treating a

proliferative disorders, especially cancer or potentiating a cancer treatment with a composition comprising at least one Chk1 inhibitor and at least one cyclodextrin. Thus, an injection solution was formulated containing a disubstituted urea Chk1 inhibitor 50 mg, Captisol 16.66 mg, HCl and NaOH to pH 4.5, and water to 1 mL. Captisol improved chemical stability of the Chk1 inhibitor compared to a solution containing a Chk1 inhibitor mesylate salt and dextrose. Degradation of Chk1 inhibitor was found to be accelerated by moisture and heat. After storage at 40°/75% RH, the Captisol-containing formulation contained 3.06 and 4.96% of related impurities after 1 and 2 mo, resp., while the non-Captisol containing formulation contained 4.41 and 7.10% of impurities at the resp. time points.

L3 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:993749 CAPLUS
DOCUMENT NUMBER: 147:330433
TITLE: Composition and method for topical treatment of tar-responsive dermatological disorders
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.; Lee, Yaling
PATENT ASSIGNEE(S): Tristrata, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 15pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070207222	A1	20070906	US 2007-680227	20070228
AU 2007223560	A1	20070913	AU 2007-223560	20070228
AU 2007223560	A2	20081016		
CA 2644311	A1	20070913	CA 2007-2644311	20070228
WO 2007103687	A2	20070913	WO 2007-US62975	20070228
WO 2007103687	A3	20081211		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1998788	A2	20081210	EP 2007-757636	20070228
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009528382	T	20090806	JP 2008-557487	20070228
CN 101460060	A	20090617	CN 2007-80015758	20081031
PRIORITY APPLN. INFO.:			US 2006-778128P	P 20060301
			WO 2007-US62975	W 20070228

AB The present invention relates to a composition including a wax and a therapeutically effective amount of tar for topical treatment of a tar-responsive dermatol. disorder, the composition being in liquid or light gel form when at a temperature selected from room temperature and a temperature of skin of a

mammal upon application of the composition to the skin of the mammal. The invention also relates to a method of treating a tar-responsive dermatol. disorder by topically applying the composition to skin of a mammal, preferably a human, that is affected by the disorder. Thus, a fast-drying liquid tar composition was formulated containing coal tar solution 15 g, ethanol 42 g, propylene glycol 5 g, cyclomethicone (DC 345) 15 g, tri-Et citrate 5 g, Brij 93 10 g, liquid wax DIADD (dioctyldodecyl dodecanedioate) 5 g, and an optional fragrance 3 g. Topical application of the composition for 4 mo to a human subject having plaque psoriasis resulted in 90% improvement of clin. signs of disorder.

L3 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1202261 CAPLUS

DOCUMENT NUMBER: 145:495768

TITLE: Soft tissue implants, anti-scarring agents, and therapeutic compositions

INVENTOR(S): Hunter, William L.; Toleikis, Philip M.; Gravett, David M.; Maiti, Arpita; Liggins, Richard T.; Takacs-Cox, Aniko; Avelar, Rui; Signore, Pierre E.; Loss, Troy A. E.; Hutchinson, Anne; McDonald-Jones, Gaye; Lakhani, Fara

PATENT ASSIGNEE(S): Angiotech International A.-G., Switz.

SOURCE: PCT Int. Appl., 2979 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006121521	A2	20061116	WO 2006-US11690	20060331
WO 2006121521	A3	20070111		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
WO 2006121522	A2	20061116	WO 2006-US11726	20060331
WO 2006121522	A3	20080502		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AP, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, EA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, EP, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, OA, BF, BJ, CF, CG, CI, CM,			

GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2005-679293P P 20050510
 US 2005-679962P P 20050510
 US 2005-679291P P 20050510

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

L3 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:493530 CAPLUS
 DOCUMENT NUMBER: 143:32415
 TITLE: Soft tissue implants and anti-scarring agents
 INVENTOR(S): Hunter, William L.; Gravett, David M.; Toleikis, Philip M.; Maiti, Arpita
 PATENT ASSIGNEE(S): Angiotech International A.-G., Switz.
 SOURCE: PCT Int. Appl., 2592 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 19
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2005051444	A2	20050609	WO 2004-US39465	20041122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050148512	A1	20050707	US 2004-986230	20041110
US 20050181977	A1	20050818	US 2004-986231	20041110
CN 101094613	A	20071226	CN 2004-80031664	20041110
AU 2004293075	A1	20050609	AU 2004-293075	20041122
CA 2536192	A1	20050609	CA 2004-2536192	20041122
WO 2005051232	A2	20050609	WO 2004-US39346	20041122
WO 2005051232	A3	20051208		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2006055008	A2	20060526	WO 2004-US39353	20041122
WO 2006055008	A3	20090416		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG,
 CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE,
 LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM, AP, EA, EP, OA

EP 1687041 A2 20060809 EP 2004-812062 20041122
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
 HR, IS, YU

CN 1878514	A	20061213	CN 2004-80033341	20041122
JP 2007514472	T	20070607	JP 2006-541689	20041122
US 20050149158	A1	20050707	US 2004-409	20041129
US 20050175662	A1	20050811	US 2004-451	20041129
US 20050175661	A1	20050811	US 2004-999205	20041129
US 20050186243	A1	20050825	US 2004-97	20041129
US 20050186242	A1	20050825	US 2004-999204	20041129
US 20050191331	A1	20050901	US 2004-1419	20041130
US 20050175663	A1	20050811	US 2004-1791	20041202
US 20050181008	A1	20050818	US 2004-1786	20041202
US 20050181011	A1	20050818	US 2004-1792	20041202
US 20050143817	A1	20050630	US 2004-6899	20041207
US 20050177103	A1	20050811	US 2004-6314	20041207
US 20050177225	A1	20050811	US 2004-6895	20041207
US 20050181004	A1	20050818	US 2004-6289	20041207
US 20060147492	A1	20060706	US 2006-343809	20060131
CN 101420970	A	20090429	CN 2004-80033576	20060515
IN 2006KN01694	A	20070511	IN 2006-KN1694	20060619
IN 2006KN01695	A	20070511	IN 2006-KN1695	20060619
IN 2006KN01698	A	20070511	IN 2006-KN1698	20060619

PRIORITY APPLN. INFO.:

US 2003-523908P	P	20031120
US 2003-524023P	P	20031120
US 2003-525226P	P	20031124
US 2003-526541P	P	20031203
US 2004-578471P	P	20040609
US 2004-586861P	P	20040709
US 2004-986230	A	20041110
US 2004-986231	A	20041110
US 2003-518785P	P	20031110
US 2004-582833P	P	20040624
US 2004-986450	A1	20041110
WO 2004-US37930	W	20041110
WO 2004-US39183	W	20041122
WO 2004-US39346	W	20041122
WO 2004-US39353	W	20041122
WO 2004-US39465	W	20041122

AB The invention relates to soft tissue implants for use in cosmetic or
 reconstructive surgery and to compns. to make the implants resistant to
 growth by inflammatory scar tissue. Thus, a silicone gel containing
 paclitaxel was used as a filling in breast implant.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L3 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:1036851 CAPLUS
 DOCUMENT NUMBER: 142:696

TITLE: Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
 INVENTOR(S): Kandimalla, Ekambar R.; Agrawal, Sudhir; Wang, Daqin
 PATENT ASSIGNEE(S): Hybridon, Inc., USA
 SOURCE: PCT Int. Appl., 106 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103301	A2	20041202	WO 2004-US15313	20040514
WO 2004103301	A3	20051103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004241093	A1	20041202	AU 2004-241093	20040514
CA 2526212	A1	20041202	CA 2004-2526212	20040514
US 20050009773	A1	20050113	US 2004-846167	20040514
US 7569554	B2	20090804		
EP 1628531	A2	20060301	EP 2004-752345	20040514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006528697	T	20061221	JP 2006-533117	20040514
MX 2005012421	A	20060222	MX 2005-12421	20051116
US 20080206265	A1	20080828	US 2008-20694	20080128
PRIORITY APPLN. INFO.:			US 2003-471247P	P 20030516
			US 2004-846167	A1 20040514
			WO 2004-US15313	W 20040514

OTHER SOURCE(S): MARPAT 142:696

AB The invention discloses the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:857358 CAPLUS

DOCUMENT NUMBER: 141:337747

TITLE: Oral formulations of cladribine

INVENTOR(S): Bodor, Nicholas S.; Dandiker, Yogesh

PATENT ASSIGNEE(S): Ivax Corporation, USA

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087101	A2	20041014	WO 2004-US9387	20040326
WO 2004087101	A3	20050203		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004226437	A1	20041014	AU 2004-226437	20040326
CA 2520523	A1	20041014	CA 2004-2520523	20040326
EP 1608344	A2	20051228	EP 2004-758442	20040326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008848	A	20060404	BR 2004-8848	20040326
CN 1787809	A	20060614	CN 2004-80012713	20040326
CN 100408028	C	20080806		
JP 2006521403	T	20060921	JP 2006-509371	20040326
ZA 2005007935	A	20070328	ZA 2005-7935	20040326
ZA 2005007939	A	20070328	ZA 2005-7939	20040326
US 20070197468	A1	20070823	US 2004-551205	20040326
MX 2005010329	A	20060531	MX 2005-10329	20050927
NO 2005004945	A	20051124	NO 2005-4945	20051025
PRIORITY APPLN. INFO.:			US 2003-458922P	P 20030328
			US 2003-484756P	P 20030702
			US 2004-541247P	P 20040204
			WO 2004-US9387	W 20040326

AB Provided are compns. of cladribine and cyclodextrin which are especially suited for the oral administration of cladribine. The formulations may be used to treat patients with multiple sclerosis.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:857357 CAPLUS

DOCUMENT NUMBER: 141:337746

TITLE: Cladribine formulations for improved oral and transmucosal delivery

INVENTOR(S): Bodor, Nicholas S.

PATENT ASSIGNEE(S): Ivax Corporation, USA

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2004087100	A2	20041014	WO 2004-US9384	20040326
WO 2004087100	A3	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004226435	A1	20041014	AU 2004-226435	20040326
CA 2520522	A1	20041014	CA 2004-2520522	20040326
EP 1608343	A2	20051228	EP 2004-758440	20040326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008895	A	20060411	BR 2004-8895	20040326
CN 1787810	A	20060614	CN 2004-80012714	20040326
JP 2006526009	T	20061116	JP 2006-509370	20040326
ZA 2005007935	A	20070328	ZA 2005-7935	20040326
ZA 2005007939	A	20070328	ZA 2005-7939	20040326
MX 2005010330	A	20060531	MX 2005-10330	20050927
US 20070065492	A1	20070322	US 2005-551094	20050928
IN 2005DN04555	A	20070817	IN 2005-DN4555	20051006
NO 2005004944	A	20051124	NO 2005-4944	20051025
PRIORITY APPLN. INFO.:			US 2003-458922P	P 20030328
			US 2003-484756P	P 20030702
			US 2004-541246P	P 20040204
			WO 2004-US9384	W 20040326
AB Provided are compns. of cladribine and cyclodextrin which are especially suited for the oral and buccal administration of cladribine.				
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L3 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:780831 CAPLUS

DOCUMENT NUMBER: 141:282824

TITLE: Controlled release implant formulations for cell-schedule dependent anticancer agents

INVENTOR(S): Warren, Stephen L.; Dadey, Eric J.; Zhou, Mingxing; Dunn, Richard L.

PATENT ASSIGNEE(S): Atrix Laboratories, Inc., USA

SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2004081196	A2	20040923	WO 2004-US7650	20040311
WO 2004081196	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

AU 2004219595 A1 20040923 AU 2004-219595 20040311
CA 2518791 A1 20040923 CA 2004-2518791 20040311
EP 1622540 A2 20060208 EP 2004-719856 20040311

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

JP 2007525429 T 20070906 JP 2006-507133 20040311
US 20060121085 A1 20060608 US 2005-222668 20050909

PRIORITY APPLN. INFO.:

US 2003-454100P P 20030311
US 2003-505124P P 20030922
WO 2004-US7650 W 20040311

AB The present invention provides a flowable composition suitable for use as a controlled release implant. The composition includes: (a) a biodegradable, biocompatible thermoplastic polymer that is at least substantially insol. in aqueous medium, water or body fluid; (b) a cell-cycle dependent biol. agent, a schedule-dependent biol. agent, a metabolite thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (c) a biocompatible organic liquid, at standard temperature and pressure, in which

the

thermoplastic polymer is soluble The present invention also provides a method of treating cancer in a mammal. The present invention also provides a method of blocking, impeding, or otherwise interfering with cell cycle progression at the G1-phase, G1/S interphase, S-phase, G2/M interface or M-phase of the cell cycle in a mammal. The methods includes administering to a mammal an effective amount of a flowable composition of the present invention. Examples demonstrate the feasibility and efficacy potential for intratumoral delivery of Floxuridine in the Atrigel (glycolide-lactide copolymer) delivery system to an animal tumor model.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:521462 CAPLUS

DOCUMENT NUMBER: 137:88442

TITLE: Incensole and furanogermacrene and compounds in treatment for inhibiting neoplastic lesions and microorganisms

INVENTOR(S): Shanahan-Pendergast, Elisabeth

PATENT ASSIGNEE(S): Ire.

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053138	A2	20020711	WO 2002-IE1	20020102
WO 2002053138	A3	20020919		

W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD,

UA, UG, US, VN, YU, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI,
 ML, MR, NE, SN, TD, TG
 AU 2002219472 A1 20020716 AU 2002-219472 20020102
 EP 1351678 A2 20031015 EP 2002-727007 20020102
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 20040092583 A1 20040513 US 2004-250535 20040102
 PRIORITY APPLN. INFO.: IE 2001-2 A 20010102
 WO 2002-IE1 W 20020102

OTHER SOURCE(S): MARPAT 137:88442

AB The invention discloses the use of incensole and/or furanogermacrene, derivatives, metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immunodysregulatory disorders. These compounds can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacrene and their mixture showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.

OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:300514 CAPLUS

DOCUMENT NUMBER: 134:331617

TITLE: Oil-in-water emulsion compositions for polyfunctional active ingredients

INVENTOR(S): Chen, Feng-jing; Patel, Mahesh V.

PATENT ASSIGNEE(S): Lipocine, Inc., USA

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001028555	A1	20010426	WO 2000-US28835	20001018
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 20020107265	A1	20020808	US 1999-420159	19991018
US 6720001	B2	20040413		

PRIORITY APPLN. INFO.: US 1999-420159 A 19991018

AB Pharmaceutical oil-in-water emulsions for delivery of polyfunctional active ingredients with improved loading capacity, enhanced stability, and reduced irritation and local toxicity are described. Emulsions include an aqueous phase, an oil phase comprising a structured triglyceride, and an emulsifier. The structured triglyceride of the oil phase is substantially free of triglycerides having three medium chain (C6-C12) fatty acid

moieties, or a combination of a long chain triglyceride and a polarity-enhancing polarity modifier. The present invention also provides methods of treating an animal with a polyfunctional active ingredient, using dosage forms of the pharmaceutical emulsions. For example, an emulsion was prepared, with cyclosporin A as the polyfunctional active ingredient dissolved in an oil phase including a structured triglyceride (Captex 810D) and a long chain triglyceride (safflower oil). The composition contained (by weight) cyclosporin A 1.0, Captex 810D 5.0, safflower oil 5.0, BHT 0.02, egg phospholipid 2.4, dimyristoylphosphatidyl glycerol 0.2, glycerol 2.25, EDTA 0.01, and water up to 100%, resp.

OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS
RECORD (17 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:38:46 ON 10 SEP 2009)

FILE 'REGISTRY' ENTERED AT 13:38:55 ON 10 SEP 2009

E CLADRIBINE/CN
L1 1 S E3
E CYCLODEXTRIN/CN
L2 1 S E3

FILE 'CAPLUS' ENTERED AT 13:39:31 ON 10 SEP 2009

L3 12 S L1 AND L2
L4 6 S L3 AND PY<=2004

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	40.24	55.74
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.84	-9.84

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:42:04 ON 10 SEP 2009

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajsl1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 14:31:02 ON 10 SEP 2009
FILE 'CAPLUS' ENTERED AT 14:31:02 ON 10 SEP 2009
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
----------------------	---------------------	------------------

FULL ESTIMATED COST	40.24	55.74
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-9.84	-9.84

=> d his

(FILE 'HOME' ENTERED AT 13:38:46 ON 10 SEP 2009)

FILE 'REGISTRY' ENTERED AT 13:38:55 ON 10 SEP 2009

	E CLADRIBINE/CN
L1	1 S E3
	E CYCLODEXTRIN/CN
L2	1 S E3

FILE 'CAPLUS' ENTERED AT 13:39:31 ON 10 SEP 2009

L3	12 S L1 AND L2
L4	6 S L3 AND PY<=2004

=> s l2 and (purine or adenosine) and (inclusion or complex) and amorphous

	7414 L2
	42133 PURINE
	12214 PURINES
	46736 PURINE
	(PURINE OR PURINES)
	98553 ADENOSINE
	819 ADENOSINES
	98749 ADENOSINE
	(ADENOSINE OR ADENOSINES)
	135543 INCLUSION
	73659 INCLUSIONS
	181483 INCLUSION
	(INCLUSION OR INCLUSIONS)
	1507827 COMPLEX
	816567 COMPLEXES
	1831504 COMPLEX
	(COMPLEX OR COMPLEXES)
	301262 AMORPHOUS
	5 AMORPHOUSES
	301266 AMORPHOUS
	(AMORPHOUS OR AMORPHOUSES)
L5	0 L2 AND (PURINE OR ADENOSINE) AND (INCLUSION OR COMPLEX) AND AMORPHOUS

=> s l2 and (purine or adenosine) and (inclusion or complex)

	7414 L2
	42133 PURINE
	12214 PURINES
	46736 PURINE
	(PURINE OR PURINES)
	98553 ADENOSINE
	819 ADENOSINES
	98749 ADENOSINE
	(ADENOSINE OR ADENOSINES)
	135543 INCLUSION
	73659 INCLUSIONS
	181483 INCLUSION
	(INCLUSION OR INCLUSIONS)

1507827 COMPLEX
816567 COMPLEXES
1831504 COMPLEX

(COMPLEX OR COMPLEXES)

L6 13 L2 AND (PURINE OR ADENOSINE) AND (INCLUSION OR COMPLEX)

=> s 16 and py<=2004

25141550 PY<=2004

L7 8 L6 AND PY<=2004

=> d 17 1-8 ibib abs

L7 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:521462 CAPLUS

DOCUMENT NUMBER: 137:88442

TITLE: Incensole and furanogermacrene and compounds in treatment for inhibiting neoplastic lesions and microorganisms

INVENTOR(S): Shanahan-Pendergast, Elisabeth

PATENT ASSIGNEE(S): Ire.

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053138	A2	20020711	WO 2002-IE1	20020102 <--
WO 2002053138	A3	20020919		
W:	AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG			
AU 2002219472	A1	20020716	AU 2002-219472	20020102 <--
EP 1351678	A2	20031015	EP 2002-727007	20020102 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 20040092583	A1	20040513	US 2004-250535	20040102 <--
PRIORITY APPLN. INFO.:			IE 2001-2	A 20010102
			WO 2002-IE1	W 20020102

OTHER SOURCE(S): MARPAT 137:88442

AB The invention discloses the use of incensole and/or furanogermacrene, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immunodysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacrene and their mixture showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.

OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:95053 CAPLUS

DOCUMENT NUMBER: 132:242544

TITLE: Advanced statistical evaluation of complex formation constant from electrophoretic data
 AUTHOR(S): Bartak, P.; Bednar, P.; Kubacek, L.; Stransky, Z.
 CORPORATE SOURCE: Trida Svobody 8, Centre of Bioanalytical Research, Palacky University, Olomouc, 771 46, Czech Rep.
 SOURCE: Analytica Chimica Acta (2000), 407(1-2), 327-336
 CODEN: ACACAM; ISSN: 0003-2670
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A new method for the estimation of complex formation consts. is presented. The method is based on electrophoretically measured effective mobilities and applied to the estimation of the complex formation constant in respect to interactions between nitrogen heterocyclic bases and cyclodextrines. The calcn. of consts. is based on the linearization of the dependence between effective mobility and the cyclodextrine concentration

and

the application of an advanced statistical evaluation procedure. Complex formation consts. 14.8 and 63.2 l/mol were obtained for the interaction of pyridinium and benzylaminopurinium with dimethyl- β -cyclodextrin (DM- β -CD), resp. Consts. in the order of magnitude 10¹-10² l/mol were obtained for some other purine derivs. The proposed procedure, in connection with the math. software for matrix operations, is rather simple and gives much more valuable outputs than commonly used concepts.

OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:65552 CAPLUS

DOCUMENT NUMBER: 132:127462

TITLE: Particles, in particular micro- or nanoparticles, of crosslinked mono- and oligosaccharides, their production, and cosmetic, pharmaceutical, or food compositions containing them

INVENTOR(S): Perrier, Eric; Rey-Goutenoire, Sylvie; Buffevant, Chantal; Levy, Marie-Christine; Pariot, Nadine; Edwards, Florence; Andry, Marie-Christine

PATENT ASSIGNEE(S): Coletica, Fr.

SOURCE: Ger. Offen., 34 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 19932216	A1	20000127	DE 1999-19932216	19990709 <--
DE 19932216	B4	20051208		
FR 2780901	A1	20000114	FR 1998-8809	19980709 <--
FR 2780901	B1	20000929		
NL 1012517	C2	20000111	NL 1999-1012517	19990705 <--
KR 2000011579	A	20000225	KR 1999-27476	19990708 <--
KR 799407	B1	20080130		
JP 2000038402	A	20000208	JP 1999-196705	19990709 <--

JP 3437797	B2	20030818		
US 6197757	B1	20010306	US 1999-350131	19990709 <--
ES 2155793	A1	20010516	ES 1999-1547	19990709 <--
ES 2155793	B1	20011201		
IT 1311514	B1	20020313	IT 1999-TO599	19990709 <--
			FR 1998-8809	A 19980709

PRIORITY APPLN. INFO.:

AB Particles consisting of ≥ 1 mono- or oligosaccharide, which are surface-crosslinked in emulsion by esterification of primary OH groups on the saccharides with a polyfunctional acylating agent, are useful as carriers or encapsulating agents for various hydrophilic or lipophilic active substances in preparation of cosmetic, pharmaceutical, or food compns. The particles are biocompatible, biodegradable, and suitable for stabilization and protection of sensitive active substances or for their sustained release. The crosslinking reaction preferably occurs in a water-in-oil emulsion at room temperature and results in formation of a

membrane

of crosslinked saccharide surrounding an aqueous phase. The saccharide may be a cyclodextrin; by forming an inclusion compound with an active substance, it can be used to remove or harvest the latter from a liquid medium, or alternatively can slowly release an active substance from an inclusion compound. Thus, 6 mL of a 10% solution of dihydroxyacetone (a ketose) in 1M carbonate buffer (pH 11) was emulsified in 30 mL cyclohexane containing 5% Span 85, and with continued stirring, 40 mL of a 5% solution of terephthaloyl chloride in CHCl₃-cyclohexane (1:4 by volume); after 30 min, the microcapsules were collected and washed. These microcapsules dissolved slowly in 1% Na₂CO₃ solution or in PEG owing to alcoholysis of the ester bonds; the released dihydroxyacetone reacted with glycine to form a brown color. The microcapsules can therefore be used in cosmetic tanning preps.

OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

L7 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:549161 CAPLUS

DOCUMENT NUMBER: 131:175082

TITLE: High-energy cyclodextrin-drug complexes with increased bioavailability

INVENTOR(S): Loftsson, Thorsteinn; Masson, Mar; Stefansson, Einar

PATENT ASSIGNEE(S): Cyclops, Iceland

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9942111	A1	19990826	WO 1999-IS3	19990216 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2320772	A1	19990826	CA 1999-2320772	19990216 <--
AU 9926385	A	19990906	AU 1999-26385	19990216 <--

AU 759280	B2	20030410		
EP 1067942	A1	20010117	EP 1999-906440	19990216 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NZ 505951	A	20030228	NZ 1999-505951	19990216 <--
JP 2003522207	T	20030722	JP 2000-532126	19990216 <--
US 6699849	B1	20040302	US 1999-250185	19990216 <--
US 20040186075	A1	20040923	US 2004-750940	20040105 <--
PRIORITY APPLN. INFO.:			US 1998-75544P	P 19980223
			US 1999-250185	A1 19990216
			WO 1999-IS3	W 19990216

AB Methods for enhancing the complexation efficiency of a drug with cyclodextrin and for enhancing the availability of a drug following administration of a cyclodextrin-drug complex. Phenytoin-2-hydroxypropyl β -cyclodextrin complexes were prepared, lyophilized to a powder which can be formulated into tablets. The bioavailability of phenytoin was enhanced.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:727151 CAPLUS

DOCUMENT NUMBER: 128:23072

ORIGINAL REFERENCE NO.: 128:4531a, 4534a

TITLE: Oligosaccharide analogs of polysaccharides. Part 14. Carbocyclic cyclodextrin analogs. Synthesis of all trimeric and tetrameric isomers by homo- and heterocoupling of 1,4-cis-diethynylated 1,5-anhydroglucitols

AUTHOR(S): Burli, Roland; Vasella, Andrea

CORPORATE SOURCE: Lab. Organische Chemie, ETH-Zentrum, Zurich, CH-8092, Switz.

SOURCE: Helvetica Chimica Acta (1997), 80(7), 2215-2237

CODEN: HCACAV; ISSN: 0018-019X

PUBLISHER: Verlag Helvetica Chimica Acta

DOCUMENT TYPE: Journal

LANGUAGE: English

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Hetero- or homocoupling of protected 1,4-cis-diethynylated 1,5-anhydroglucitols leads to 2 isomeric cyclotrimers and to 4 isomeric cyclotetramers. The C1-sym. cyclotrimer I and the C1- and the C2-sym. cyclotetramers II and III, resp., were prepared. The cyclotrimer I was prepared by intramol., oxidative homocoupling and, alternatively, by a 1-pot trimerization/cyclization of the monomer. Oxidative homocoupling was used for the cyclization of appropriate tetramers to II and III. The acyclic tetramers were made by sequential Cadot-Chodkiewicz coupling or by a combination of a Cadot-Chodkiewicz reaction and an intermol., oxidative homocoupling. The solid-state conformation of a C4-sym. cyclotetramer corresponds well to the one predicted by force-field calcns. The water-solubilities of cyclotrimers and -tetramers, their calculated

conformations, and the D-adenosine binding properties of the cyclotetramers were compared.

OS.CITING REF COUNT: 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)

L7 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:711646 CAPLUS

DOCUMENT NUMBER: 121:311646

ORIGINAL REFERENCE NO.: 121:56853a,56856a

TITLE: Proton Transfer and $n \rightarrow \pi^*$ Transition in the Photophysics of 1,N6-Ethenoadenosine

AUTHOR(S): Agbaria, Rezik A.; Parola, Abraham H.; Gill, David

CORPORATE SOURCE: Department of Physics, Ben-Gurion University, Beer-Sheva, 84105, Israel

SOURCE: Journal of Physical Chemistry (1994), 98(50), 13280-5

CODEN: JPCHAX; ISSN: 0022-3654

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The photophys. characteristics of 1,N6-ethenoadenosine (ϵ Ado) show irregularities in terms of the expected photophysics from a pH equilibrium between two forms that absorb light at different wavelengths. Furthermore, a comparison between the absorption spectra of purine, adenine, and ϵ Ado leads to the conclusion that ϵ Ado does not follow the adenine, but rather has more in common with the purine. The adenine itself does not follow its parent compound, purine. We, therefore, reinterpret the absorption of ϵ Ado, such as the unprotonated form has two absorption bands, the second of which is an $n \rightarrow \pi^*$ transition, whereas the protonated form has only one $\pi \rightarrow \pi^*$ absorption band, which overlaps with the first absorption band of the unprotonated form. The $n \rightarrow \pi^*$ absorption "disappeared" upon protonation, apparently due to stabilization of the lone-pair electrons. Under these presumptions, the photophysics of ϵ Ado is no longer peculiar. Transitions to and from both excited singlet states, $S\pi\pi^*$ and $S_n\pi^*$, along with the relative order of their resp. triplets, are shown to play an active role in the photophysics of ϵ Ado. Therefore, the reported multiple emissions from ϵ Ado, at low temperature, are to be expected. The reported observations in the literature provide evidence for the multiple excited states of ϵ Ado. In the present work, cyclodextrins provide a powerful tool in the photophys. study of ϵ Ado. In particular, cyclodextrin host isolation matrix (CHIM) provides a unique environment that can be applied to mimic the photophysics of the isolated mol. in the gas phase or at low temps.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L7 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:69602 CAPLUS

DOCUMENT NUMBER: 120:69602

ORIGINAL REFERENCE NO.: 120:12359a,12362a

TITLE: Preparation and use of polyanionic polymer-based conjugates targeted to vascular endothelial cells

INVENTOR(S): Thorpe, Philip E.

PATENT ASSIGNEE(S): University of Texas System, USA; Imperial Cancer Research Technology Ltd.

SOURCE: PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9318793	A1	19930930	WO 1993-US2619	19930322 <--
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, KP, KR, LU, MG, MN, MW, NL, NO, PL, PT, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR				
US 5474765	A	19951212	US 1992-856018	19920323 <--
AU 9338166	A	19931021	AU 1993-38166	19930322 <--
EP 632728	A1	19950111	EP 1993-907633	19930322 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT				
US 5762918	A	19980609	US 1994-307745	19941205 <--
PRIORITY APPLN. INFO.:			US 1992-856018	A2 19920323
			WO 1993-US2619	A 19930322

AB An anionic polymer (e.g. a heparin derivative) is linked to an active agent (especially a steroid), preferably by a selectively hydrolyzable bond, for delivery of the active agent to vascular endothelial cells. The conjugates are useful as angiogenesis inhibitors for treatment of e.g. cancer, arthritis, and diabetic blindness. Thus, heparin was condensed with adipic dihydrazide and then with cortisol; the cortisol:heparin mol ratio in the product was 8-9. This conjugate was markedly acid labile, suppressed DNA synthesis and cell migration in human umbilical vein endothelial cells, retarded or abolished the vascularization of sponges in vivo, and retarded lung tumor growth in mice by 65%. No adverse effects of the conjugate were detected, and equivalent treatments with a mixture of heparin and cortisol were significantly less effective in all cases.

OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:637813 CAPLUS

DOCUMENT NUMBER: 119:237813

ORIGINAL REFERENCE NO.: 119:42169a, 42172a

TITLE: Dye transfer thermal printing process. VI. Prevention of image decoloration in dye transfer recording

AUTHOR(S): Kusakawa, Hideaki; Enmanji, Koe

CORPORATE SOURCE: Kanazawa Inst. Technol., Nonoichi, 721, Japan

SOURCE: Denshi Shashin Gakkaishi (1993), 32(1), 3-6
CODEN: DSHGDD; ISSN: 0387-916X

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB The thermal dye transfer color ink, which is developed to have same sensitivity as the com. used thermal printing paper for G-II type facsimile, is composed of dyes such as SOT-Blue 2, -Red 2G, and -Yellow 5 with suitable binder polymers. The light fastness of these dyes is low. Thus, it is necessary to improve it, especially, for -Blue 2. Decoloration of the dye is prevented either by charge-transfer complex formation or the inclusion of the dyes. For binder polymers such as PMMA, in which the dye is dissolved rather than dispersed, it is not possible to form charge-transfer complexes and improvement of light fastness is not observed. For polar binder polymers such as poly(vinyl alc.), in which the dye and electron-acceptor particles are dispersed rather than dissolved, it was necessary to add electron-acceptor to form

complexes. The dye mol. is too large for cyclodextrin to enclose it, and, accordingly, the improvement in light fastness was not so remarkable.

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

87.64

103.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-16.40

-16.40

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 14:32:22 ON 10 SEP 2009